世界中医药

目的：探讨参附注射液对慢性阻塞性肺疾病患者血液流变学及C反应蛋白的影响。方法：选择2013年9月至2014年10月来我院治疗慢性阻塞性肺疾病患者84例，随机分成对照组和观察组2组，每组42例。对照组患者采用常规西药加氟替卡松治疗，观察组患者在对照组患者治疗基础上加用参附注射液治疗。结果：治疗后，观察组患者FEV1水平(1.68±0.35) L、FVC水平(2.80±0.42) L及FEV1/FVC水平(59.62±13.61)%均高于对照组患者FEV1水平(1.33±0.59) L、FVC水平(2.39±0.54) L及FEV1/FVC水平(54.15±10.76)%，差异具有统计学意义(P<0.01)。治疗后，观察组患者血浆IL-8水平(40.18±8.86) pg/mL、TNF-α水平(53.01±5.42) pg/mL及CRP水平(5.06±4.25) μg/mL均低于对照组患者血浆IL-8水平(47.48±6.55) pg/mL、TNF-α水平(60.51±6.41) pg/mL及CRP水平(7.28±5.43) μg/mL，差异具有统计学意义(P<0.05)。治疗后，观察组患者血液流变学指标全血比黏度水平(2.71±0.32) mPa·s、血浆比黏度水平(1.03±0.11) mPa·s、红细胞压积水平(0.32±0.04)%、纤维蛋白原水平(2.41±0.72) g/L均低于对照组患者全血比黏度水平(3.55±0.22) mPa·s、血浆比黏度水平(1.61±0.19) mPa·s、红细胞压积水平(0.43±0.05)%、纤维蛋白原水平(3.61±0.58) g/L，差异具有统计学意义(P<0.05)。治疗后，观察组患者是慢性阻塞性肺疾病急性加重（Acute Exacerbation of Chronic Obstructive Pulmonary Disease，AECOPD）发作次数(1.05±0.21)次少于对照组患者AECOPD发作次数(1.18±0.25)次，差异具有统计学意义(P<0.05)。结论：慢性阻塞性肺疾病患者在常规西药治疗基础上加用参附注射液能有效的提高治疗效果，改善患者血液流变学指标，降低患者急性加重发作次数，提高肺功能。

English Summary:

To explore the effect of Shenfu Injection on the hemorrheological index and C-reactive protein in patients with chronic obstructive pulmonary disease. Methods:Total 84 cases of patients with chronic obstructive pulmonary disease who had received treatment in our hospital between September 2013 and October 2014 were selected, and then randomly divided into control group and observation group, with 42 cases in each group. Patients in the control group were treated by routine western medicine of Fluticasone, whereas those in the control group were treated with Shenfu Injection additional to the treatment given to the control group. Results: After treatment, the levels of FEV1, FVC and FEV1/FVC in the observation group were respectively (1.68±0.35)L, (2.80±0.42)L, and (59.62±13.61)%， all significantly higher than those in the control group, which were respectively (1.33±0.59)L, (2.39±0.54)L, and (54.15±10.76)%, with significant differences (P<0.01). After treatment, the levels of plasma IL-8, TNF-α and C-reactive protein (CRP) in the observation group were respectively (40.18±886)pg/ml, (53.01±5.42)pg/ml, and (5.06±4.25)μg/ml, all lower than those in the control group, which were respectively (47.48±6.55)pg/ml, (60.51±641)pg/ml and (7.28±5.43)μg/ml, and the difference was statistically significant (P<0.05). After treatment, the level of blood rheology indexes of whole blood viscosity, plasma viscosity, hematocrit and fibrinogen in the observation group were respectively (2.71±0.32)mPa·s, (1.03±0.11)mPa·s, (0.04±0.32)g/L, and (0.72±0.22)mPa·s, all lower than those in the control group, which were respectively (3.55±0.22)mPa·s, (1.61±0.19)mPa·s, (0.43±0.05)% and (3.61±0.58)g/L, and the differences were statistically significant (P<0.05). After treatment, the number of AECOPD attacks in the observation group was (1.05±0.21) times, less than that in the control group, which was (0.21±0.25) times, and the difference was statistically significant (P<0.05). Conclusion: In the treatment of chronic obstructive pulmonary disease, Shenfu Injection combined with routine western medicine can effectively improve the treatment effects and blood rheology indicators, as well as reduce acute exacerbation and boost lung function of the patients.

查看全文查看/发表评论下载PDF阅读器